Syurvival prognosis and target therapy results in chronic myeloid leukemia patients

Chronic myeloid leukemia (CML) is amalignant neoplasm of hematopoietic tissue associated with a characteristic chromosomal (Philadelphia chromosome) abnormality. For the treatmentof chronic myeloid leukemia was first developedhigh-precision targeted therapy with a special classof drugs - tyrosine kinase inhibitors (TKI), whichhad changed the CML prognosis. At present the aimof CML therapy is maximum suppression of tumorclone, reducing the risk of disease progression,achieving life expectancy of patients comparableto the General population. Achieving a completecytogenetic response (CCyR) and a major molecularresponse (MMR) are early favorable prognosticsigns of longterm progression-free survival withcontinued therapy. Currently, TKI is the primarytreatment for CML and has a proven advantageover other treatments modalities. Therapy of the first and second line TKI shouldbe chosen taking into account the highest efficiencyand the lowest risk of side effects. Early evaluationof treatment response, prevention of resistance development and rapid switching to the most effectivetherapy in the absence of optimal response shouldbe the basic principles of modern cMl therapy. The aim of this work was to study the prognosisand effectiveness of targeted therapy of chronicmyeloid leukemia and its change according to molecular genetic monitoring. To conduct the study were analyzed the resultsof diagnosis and treatment of 307 patients withCML observed at our institution in the period 2005- 2018. A comparison of prognostic scales for predicting overall (OS) and progression-free survival.